Microbiotica announced as a finalist in ‘Best Partnership Alliance’ category at Scrip Awards 2019

Cambridge, UK, 18 September 2019 – Microbiotica, a leading player in microbiome-based live therapeutics, has been selected as a finalist in the ‘Best Partnership Alliance’ category at the Scrip Awards 2019. The winners will be announced on 4 December 2019.

Microbiotica has been recognised for its multi-year strategic collaboration with Genentech, which was announced in June 2018. The collaboration, worth up to $534 million, is to discover develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD). Under the agreement, Microbiotica is utilising its precision metagenomics microbiome platform to analyse patient samples from clinical trials of Genentech’s investigational IBD medicines.

The Scrip Awards, now in their 15th year, seek to recognise the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. The awards span the entire range of industry activities, from new drug launches and clinical trials, to innovative deals, outsourcing and funding.

Dr Mike Romanos, CEO of Microbiotica, said: “The Scrip Awards are one of our industry’s most prestigious awards, as they are judged by an independent panel of world-class experts from across the sector. It is a great validation of our ongoing strategic collaboration with Genentech to be chosen as a finalist for the Best Partnership Alliance award.”

Details of the awards ceremony are as follows:

Scrip Awards 2019
Date: 4 December 2019
Venue: The Hilton on Park Lane, London

For more information, see here: https://pharmaintelligence.informa.com/events/awards/scrip-awards-2019